UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 31.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Rieger, J; Bähr, O; Maurer, G D; Hattingen, E; Franz, K; Brucker, D; Walenta, S; Kämmerer, U; Coy, J F; Weller, M; Steinbach, J P (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma / Erratum. International Journal of Oncology, 45(6):2605.

Rieger, J; Bähr, O; Maurer, G D; Hattingen, E; Franz, K; Brucker, D; Walenta, S; Kämmerer, U; Coy, J F; Weller, M; Steinbach, J P (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. International Journal of Oncology, 44(6):1843-1852.

Fischer, S; Ronellenfitsch, M W; Thiepold, A L; Harter, P N; Reichert, S; Kögel, D; Paschke, R; Mittelbronn, M; Weller, M; Steinbach, J P; Fulda, S; Bähr, O (2014). Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic Acid. PLoS ONE, 9(4):e94921.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Blaes, J; Weiler, M; Sahm, F; Hentschel, B; Osswald, M; Czabanka, M; Thomé, C M; Schliesser, M G; Pusch, S; Luger, S; Winkler, F; Radbruch, A; Jugold, M; Simon, M; Steinbach, J P; Schackert, G; Tatagiba, M; Westphal, M; Tonn, J C; Gramatzki, D; Pietsch, T; Hartmann, C; Glimm, H; Vajkoczy, P; von Deimling, A; Platten, M; Weller, M; Wick, W (2014). NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 117(1):25-32.

Wiestler, B; Claus, R; Hartlieb, S A; Schliesser, M G; Weiss, E K; Hielscher, T; Platten, M; Dittmann, L M; Meisner, C; Felsberg, J; Happold, C; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Grimm, C; Weichenhan, D; Tews, B; Reifenberger, G; Capper, D; Müller, W; Plass, C; Weller, M; Wick, W (2013). Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 15(8):1017-1026.

Bähr, O; Hermisson, M; Rona, S; Rieger, J; Nussbaumer, S; Körtvelyessy, P; Franz, K; Tatagiba, M; Seifert, V; Weller, M; Steinbach, J P (2012). Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochirurgica, 154(2):229-235.

Burger, M C; Brucker, D P; Baumgarten, P; Ronellenfitsch, M W; Wanka, C; Hasselblatt, M; Eccles, M R; Klingebiel, T; Weller, M; Rieger, J; Mittelbronn, M; Steinbach, J P (2012). PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. International Journal of Oncology, 41(1):235-241.

Wanka, C; Brucker, D P; Bähr, O; Ronellenfitsch, M; Weller, M; Steinbach, J P; Rieger, J (2012). Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene, 31(33):3764-3776.

Wick, W; Platten, M; Meisner, C; Felsberg, J; Tabatabai, G; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Combs, S E; Vesper, J; Braun, C; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; Reifenberger, G; Weller, M (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7):707-715.

Glas, M; Bähr, O; Felsberg, J; Rasch, K; Wiewrodt, D; Schabet, M; Simon, M; Urbach, H; Steinbach, J P; Rieger, J; Fimmers, R; Bamberg, M; Nägele, T; Reifenberger, G; Weller, M; Herrlinger, U (2011). NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 70(3):445-53.

Ackermann, R; Semmler, A; Maurer, G D; Hattingen, E; Fornoff, F; Steinbach, J P; Linnebank, M (2010). Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. Journal of Neuro-Oncology, 97(3):425-427.

Dresemann, G; Weller, M; Rosenthal, M A; Wedding, U; Wagner, W; Engel, E; Heinrich, B; Mayer-Steinacker, R; Karup-Hansen, A; Fluge, O; Nowak, A; Mehdorn, M; Schleyer, E; Krex, D; Olver, I N; Steinbach, J P; Hosius, C; Sieder, C; Sorenson, G; Parker, R; Nikolova, Z (2010). Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology, 96(3):393-402.

Heese, O; Schmidt, M; Nickel, S; Berger, H; Goldbrunner, R; Tonn, J C; Bhär, O; Steinbach, J P; Simon, M; Schramm, J; Krex, D; Schackert, G; Reithmeier, T; Nikkhah, G; Löffler, M; Weller, M; Westphal, M (2010). Complementary therapy use in patients with glioma: an observational study. Neurology, 75(24):2229-2235.

Weller, M; Felsberg, J; Hartmann, C; Berger, H; Steinbach, J P; Schramm, J; Westphal, M; Schackert, G; Simon, M; Tonn, J C; Heese, O; Krex, D; Nikkhah, G; Pietsch, T; Wiestler, O; Reifenberger, G; von Deimling, A; Loeffler, M (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of Clinical Oncology, 27(34):5743-5750.

Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U (2009). Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Journal of Clinical Oncology, 27(8):1257-1261.

Ronellenfitsch, M W; Brucker, D P; Burger, M C; Wolking, S; Tritschler, F; Rieger, J; Wick, W; Weller, M; Steinbach, J P (2009). Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain: A Journal of Neurology, 132(Pt 6):1509-1522.

Bähr, O; Herrlinger, U; Weller, M; Steinbach, J P (2009). Very late relapses in glioblastoma long-term survivors. Journal of Neurology, 256(10):1756-1758.

Wischhusen, J; Jung, G; Radovanovic, I; Beier, C; Steinbach, J P; Rimner, A; Huang, H; Schulz, J B; Ohgaki, H; Aguzzi, A; Rammensee, H G; Weller, M (2002). Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Research, 62(9):2592-2599.

Steinbach, J P; Kozmik, Z; Pfeffer, P; Aguzzi, A (2001). Overexpression of Pax5 is not sufficient for neoplastic transformation of mouse neuroectoderm. International Journal of Cancer, 93(4):459-467.

Steinbach, J P; Weissenberger, J; Aguzzi, A (1999). Distinct phases of cryogenic tissue damage in the cerebral cortex of wild-type and c-fos deficient mice. Neuropathology and Applied Neurobiology, 25(6):468-480.

Pohl, U; Wick, W; Weissenberger, J; Steinbach, J P; Dichgans, J; Aguzzi, A; Weller, M (1999). Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. International Journal of Oncology, 15(4):829-834.

Sibilia, M; Steinbach, J P; Stingl, L; Aguzzi, A; Wagner, E F (1998). A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO Journal, 17(3):719-731.

Steinbach, J P; Müller, U; Leist, M; Li, Z W; Nicotera, P; Aguzzi, A (1998). Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. Cell Death and Differentiation, 5(10):858-866.

Pruschy, M; Shi, Y Q; Crompton, N E; Steinbach, J P; Aguzzi, A; Glanzmann, C; Bodis, S (1997). The proto-oncogene c-fos mediates apoptosis in murine T-lymphocytes induced by ionizing radiation and dexamethasone. Biochemical and Biophysical Research Communications (BBRC), 241(2):519-524.

Weissenberger, J; Steinbach, J P; Malin, G; Spada, S; Rülicke, T; Aguzzi, A (1997). Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene, 14(17):2005-2013.

Hafezi, F; Steinbach, J P; Marti, A; Munz, K; Wang, Z Q; Wagner, E F; Aguzzi, A; Remé, C E (1997). The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. Nature Medicine, 3(3):346-349.

Aguzzi, A; Brandner, S; Marino, S; Steinbach, J P (1996). Transgenic and knockout mice in the study of neurodegenerative diseases. Journal of Molecular Medicine, 74(3):111-126.

Steinbach, J P; Aguzzi, A (1996). XVI Winter meeting of the Swiss Society of Neuropathology, St Moritz, 20-23 March 1996. Neuropathology and Applied Neurobiology, 22(3):261-263.

Aguzzi, A; Brandner, S; Isenmann, S; Steinbach, J P; Sure, U (1995). Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia, 15(3):348-364.

This list was generated on Fri Jul 21 21:28:03 2017 CEST.